Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALICE: Atezolizumab + Chemo in Metastatic TNBC
NCT03164993Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2017
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Oslo University Hospital. Started Jun 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03164993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164993.